NDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
VUITY (pilocarpine hydrochloride) by AbbVie is clinical pharmacology: pharmacodynamics: pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. First approved in 2021.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VUITY is a topical ophthalmic solution containing pilocarpine hydrochloride, a cholinergic parasympathomimetic agent approved in October 2021. It is indicated for presbyopia (age-related loss of accommodation) and works by stimulating muscarinic receptors to increase pupil constriction (miosis) and accommodation, improving near vision. The drug represents a novel non-surgical pharmacologic approach to presbyopia management.
$0.283MPart D
Peak12.8 years to LOEProduct is in peak commercial phase with modest early uptake; brand team likely focused on market education and patient access expansion rather than rapid scaling.
Mechanism of Action
CLINICAL PHARMACOLOGY: Pharmacodynamics: Pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. Pilocarpine, in appropriate dosage, can increase secretion by the exocrine glands. The sweat, salivary, lacrimal,…
Worked on VUITY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.